Acoustic neuroma (also known as vestibular schwannoma) is a slow-growing, benign intracranial tumor arising from the Schwann cells of the eighth cranial nerve — the vestibulocochlear nerve. The tumor most commonly originates from the vestibular branch of the nerve, yet continues to be referred to as “acoustic neuroma” due to the prominent hearing loss it causes. It is typically located within the internal auditory canal and the cerebellopontine angle.
Epidemiology
Acoustic neuromas account for approximately eight percent of all intracranial tumors, with an annual incidence of 1 to 2 cases per 100,000 population. The mean age at diagnosis is in the fifth decade of life, and the condition affects men and women with equal frequency. The vast majority of cases are sporadic; however, approximately five percent are associated with neurofibromatosis type 2 (NF2), a hereditary condition characterized by bilateral acoustic neuromas.
Pathogenesis
The tumor arises from the neoplastic proliferation of Schwann cells, the myelin-producing cells of the peripheral nerve sheath. In the majority of sporadic cases, a somatic mutation is identified in the NF2 tumor suppressor gene located on the long arm of chromosome 22. This gene encodes the protein merlin, which regulates cell growth; loss of its function creates the conditions for uncontrolled Schwann cell proliferation.
Clinical Presentation
Acoustic neuroma has an insidious onset and symptoms typically emerge gradually over the course of years.
Unilateral sensorineural hearing loss is the most common presenting complaint, present in over ninety percent of patients. The hearing loss is usually gradual in onset, although sudden hearing loss can occasionally be the first manifestation.
Tinnitus is present in approximately seventy percent of patients, typically unilateral and high-pitched in character.
Vestibular symptoms manifest as imbalance and unsteadiness rather than true rotational vertigo, since the slow growth of the tumor allows sufficient time for central vestibular compensation.
Facial nerve involvement may produce facial numbness or paresis due to the intimate anatomical relationship between the tumor and the facial nerve. Motor facial palsy is a late finding and is relatively uncommon at presentation.
Trigeminal symptoms including facial numbness and pain may emerge in the setting of larger tumors compressing the fifth cranial nerve.
Hydrocephalus and brainstem compression represent advanced disease and present with headache, nausea, and gait ataxia as the tumor enlarges sufficiently to obstruct cerebrospinal fluid circulation.
Diagnosis
Magnetic resonance imaging (MRI) with gadolinium contrast is the gold standard diagnostic modality. Acoustic neuromas demonstrate homogeneous contrast enhancement on T1-weighted sequences, and the characteristic “ice cream cone” appearance within the internal auditory canal is highly supportive of the diagnosis.
Audiological evaluation encompasses pure tone audiometry and speech discrimination testing. Asymmetric pure tone average loss with a disproportionately low speech discrimination score is a classic and clinically important pattern raising suspicion for acoustic neuroma.
Auditory brainstem response (ABR) testing can serve as a screening tool, although its sensitivity is limited in the setting of small tumors and it has been largely supplanted by MRI in contemporary practice.
Treatment
Three principal treatment strategies exist, and the choice among them is individualized according to tumor size, patient age, hearing status, and overall health.
Watchful waiting (active surveillance) is appropriate for small, asymptomatic tumors, particularly in older patients. Serial MRI is used to monitor growth rate; a significant proportion of tumors demonstrate no meaningful growth over years of observation.
Stereotactic radiosurgery (Gamma Knife, CyberKnife) is applied to tumors smaller than 3 centimeters and aims to arrest tumor growth rather than eliminate it. A single high-dose radiation session is delivered with millimetric precision; local tumor control rates exceed ninety percent at ten years.
Microsurgical resection is preferred for large tumors, rapidly growing lesions, and particularly in younger patients where long-term tumor control is paramount. Three surgical approaches are employed: the translabyrinthine approach (sacrifices hearing but affords excellent facial nerve visualization), the retrosigmoid approach (hearing preservation possible), and the middle cranial fossa approach (reserved for small intracanalicular tumors with serviceable hearing).
Complications and Prognosis
The most significant surgical complications are facial nerve palsy and permanent hearing loss. Contemporary intraoperative neurophysiological monitoring has substantially improved facial nerve preservation rates. Acoustic neuroma carries an overall favorable prognosis given its benign nature; with appropriate management and regular follow-up, the majority of patients maintain a good quality of life over the long term.